Annual Accounts Receivable
$56.95 M
+$6.35 M+12.55%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual accounts receivable is currently $56.95 million, with the most recent change of +$6.35 million (+12.55%) on 31 December 2023. During the last 3 years, it has risen by +$48.30 million (+558.69%). BCRX annual accounts receivable is now at all-time high.BCRX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$72.46 M
+$3.70 M+5.38%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly accounts receivable is currently $72.46 million, with the most recent change of +$3.70 million (+5.38%) on 30 September 2024. Over the past year, it has increased by +$18.81 million (+35.06%). BCRX quarterly accounts receivable is now at all-time high.BCRX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +12.6% | +35.1% |
| 3 y3 years | +558.7% | +176.4% |
| 5 y5 years | +1226.6% | +1913.8% |
BCRX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +558.7% | at high | +176.4% |
| 5 y | 5 years | at high | +1226.6% | at high | +1913.8% |
| alltime | all time | at high | +2592.7% | at high | >+9999.0% |
BioCryst Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $72.46 M(+5.4%) |
| June 2024 | - | $68.76 M(+13.5%) |
| Mar 2024 | - | $60.59 M(+6.4%) |
| Dec 2023 | $56.95 M(+12.6%) | $56.95 M(+6.2%) |
| Sept 2023 | - | $53.65 M(-7.0%) |
| June 2023 | - | $57.67 M(+18.6%) |
| Mar 2023 | - | $48.64 M(-3.9%) |
| Dec 2022 | $50.60 M(+72.0%) | $50.60 M(+18.7%) |
| Sept 2022 | - | $42.61 M(+2.7%) |
| June 2022 | - | $41.49 M(+13.9%) |
| Mar 2022 | - | $36.41 M(+23.8%) |
| Dec 2021 | $29.41 M(+240.2%) | $29.41 M(+12.2%) |
| Sept 2021 | - | $26.21 M(-5.1%) |
| June 2021 | - | $27.62 M(+50.2%) |
| Mar 2021 | - | $18.39 M(+112.7%) |
| Dec 2020 | $8.65 M(-61.0%) | $8.65 M(+59.5%) |
| Sept 2020 | - | $5.42 M(+35.7%) |
| June 2020 | - | $4.00 M(-29.2%) |
| Mar 2020 | - | $5.64 M(-74.5%) |
| Dec 2019 | $22.15 M(+415.9%) | $22.15 M(+515.5%) |
| Sept 2019 | - | $3.60 M(-0.1%) |
| June 2019 | - | $3.60 M(-28.0%) |
| Mar 2019 | - | $5.00 M(+16.5%) |
| Dec 2018 | $4.29 M(-29.8%) | $4.29 M(+26.5%) |
| Sept 2018 | - | $3.39 M(+44.9%) |
| June 2018 | - | $2.34 M(-58.9%) |
| Mar 2018 | - | $5.69 M(-6.9%) |
| Dec 2017 | $6.12 M(-30.2%) | $6.12 M(-31.9%) |
| Sept 2017 | - | $8.98 M(+170.2%) |
| June 2017 | - | $3.33 M(-65.2%) |
| Mar 2017 | - | $9.56 M(+9.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $8.77 M(+40.4%) | $8.77 M(+46.9%) |
| Sept 2016 | - | $5.97 M(+167.1%) |
| June 2016 | - | $2.23 M(-69.7%) |
| Mar 2016 | - | $7.38 M(+18.3%) |
| Dec 2015 | $6.24 M(-34.2%) | $6.24 M(-16.7%) |
| Sept 2015 | - | $7.50 M(+74.5%) |
| June 2015 | - | $4.30 M(-23.2%) |
| Mar 2015 | - | $5.59 M(-41.1%) |
| Dec 2014 | $9.49 M(+348.7%) | $9.49 M(+193.1%) |
| Sept 2014 | - | $3.24 M(+261.0%) |
| June 2014 | - | $897.00 K(-72.7%) |
| Mar 2014 | - | $3.28 M(+55.1%) |
| Dec 2013 | $2.12 M(-53.6%) | $2.12 M(-10.7%) |
| Sept 2013 | - | $2.37 M(+131.3%) |
| June 2013 | - | $1.02 M(-76.3%) |
| Mar 2013 | - | $4.33 M(-5.2%) |
| Dec 2012 | $4.56 M(-21.8%) | $4.56 M(-21.8%) |
| Dec 2011 | $5.83 M(-80.7%) | $5.83 M(-80.7%) |
| Dec 2010 | $30.23 M(-22.7%) | $30.23 M(+130.7%) |
| Sept 2008 | - | $13.10 M(-11.8%) |
| June 2008 | - | $14.85 M(-48.0%) |
| Mar 2008 | - | $28.58 M(-27.0%) |
| Dec 2007 | $39.13 M(+758.8%) | $39.13 M(+88.6%) |
| Sept 2007 | - | $20.75 M(+13.5%) |
| June 2007 | - | $18.27 M(+118.4%) |
| Mar 2007 | - | $8.37 M(+83.6%) |
| Dec 2006 | $4.56 M(-84.8%) | $4.56 M(+45.1%) |
| Sept 2006 | - | $3.14 M(+58.9%) |
| June 2006 | - | $1.98 M(+213.5%) |
| Mar 2006 | - | $630.00 K(-97.9%) |
| Dec 2005 | $30.00 M | $30.00 M |
FAQ
- What is BioCryst Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual accounts receivable year-on-year change?
- What is BioCryst Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly accounts receivable year-on-year change?
What is BioCryst Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of BCRX is $56.95 M
What is the all time high annual accounts receivable for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual accounts receivable is $56.95 M
What is BioCryst Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, BCRX annual accounts receivable has changed by +$6.35 M (+12.55%)
What is BioCryst Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of BCRX is $72.46 M
What is the all time high quarterly accounts receivable for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly accounts receivable is $72.46 M
What is BioCryst Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, BCRX quarterly accounts receivable has changed by +$18.81 M (+35.06%)